Eli Lilly Strikes a New Deal Beyond Obesity Drugs
Eli Lilly expands beyond its blockbuster obesity treatments while fresh caution surfaces around Nvidia heading into the close.
If you've been watching Eli Lilly mostly for its weight-loss drug headlines, here's a reminder that the company has a lot more going on under the hood. The pharma giant has inked a new deal that steps outside its now-famous obesity franchise — a signal that management is actively diversifying its pipeline and not putting all its eggs in the GLP-1 basket.
Meanwhile, Nvidia continues to be the stock everyone has an opinion on, and the latest nudge from analysts is another gentle pump of the brakes. This marks at least one more voice urging investors to temper their enthusiasm, even as the chipmaker remains a dominant force in the artificial intelligence infrastructure buildout. When multiple cautionary flags appear in a short window, it's worth paying attention — even if you're a long-term bull.
Read more iShares S&P 500 Growth ETF Added $207M Thursday, NVIDIA on Top →
Both storylines dropped in the CNBC Investing Club's "Homestretch" — the daily afternoon update designed to give members actionable context heading into the final hour of the trading session. Think of it as a quick gut-check before the closing bell rings and you're left wondering what just happened to your portfolio.
For everyday investors, the Lilly news is a useful reminder that diversification isn't just a personal-finance buzzword — it's something the biggest companies in the world practice too. And the Nvidia caution is a good prompt to revisit position sizing if the stock has grown to dominate your holdings more than you intended.
Continue reading at US Top News and Analysis